China Manufacturing Landscape for Oclacitinib (CAS 1208319-26-9)
Oclacitinib, the Janus Kinase (JAK) inhibitor revolutionizing veterinary dermatology for the treatment of canine allergic and atopic dermatitis, represents one of the most commercially dynamic veterinary APIs in current production. Our production facility in Zhejiang Province has developed a validated synthesis of Oclacitinib maleate, providing veterinary pharmaceutical companies with an alternative supply source for this high-demand compound. As a China-based direct manufacturer, we combine synthetic chemistry expertise with competitive competitive pricing.
The growing global demand for Oclacitinib — driven by increasing pet ownership, rising veterinary healthcare spending, and the compound’s superior efficacy profile versus traditional corticosteroid treatments — has created significant market opportunities for qualified API manufacturers. Our production capability helps veterinary pharmaceutical formulators secure reliable supply in this expanding market.
Manufacturing Process & Facility
Our Oclacitinib maleate synthesis employs a multi-step chemical process featuring key heterocyclic construction chemistry to build the pyrrolopyrimidine core structure. The synthesis includes chiral resolution steps, amide bond formation, and salt formation with maleic acid, followed by controlled crystallization to achieve the desired polymorphic form. Each synthetic step has been extensively optimized for yield, purity, and scalability.
Key facility specifications:
- Dedicated synthesis suites with glass-lined and Hastelloy reactors (200L to 3000L)
- ISO Class 7 cleanroom environments for final isolation and packaging
- Automated process control with real-time analytical monitoring via PAT (Process Analytical Technology)
- Chiral chromatography capability for enantiomeric purification
- Annual production capacity: 1.5 metric tons of Oclacitinib maleate API
- Dedicated R&D laboratory for continuous process improvement
Our process chemistry team has developed a synthesis route with an overall yield that is highly competitive, and ongoing optimization efforts focus on reducing step count and improving atom economy.
Quality Standards & Multi-Pharmacopeial Compliance
Our Oclacitinib maleate API is manufactured to stringent internal specifications aligned with veterinary pharmaceutical requirements:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Identification | Positive by IR, HPLC, MS | IR/HPLC/MS |
| Assay (anhydrous basis) | ≥98.0% | HPLC |
| Chiral Purity | ≥99.0% ee | Chiral HPLC |
| Related Substances (total) | ≤1.0% | HPLC |
| Any Single Impurity | ≤0.15% | HPLC |
| Residual Solvents | Meets ICH Q3C | GC-HS |
| Elemental Impurities | Meets ICH Q3D | ICP-MS |
| Water Content | ≤0.5% | Karl Fischer |
| Polymorphic Form | Form I (confirmed by XRPD) | X-Ray Powder Diffraction |
Regulatory Documentation
We provide complete regulatory support for Oclacitinib maleate API registration:
- Drug Master File available for cross-reference in US FDA CVM submissions
- EU ASMF prepared for veterinary medicinal product applications
- China NMPA registration for veterinary API manufacturing
- Complete process validation package with three consecutive commercial-scale batches
- Stability data per VICH GL3/GL5 guidelines with 24-month results
- Complete impurity profile with synthesis of reference standards
- Polymorphic form characterization and stability studies
- Genotoxic impurity assessment per ICH M7
Our regulatory affairs team collaborates closely with customers to support efficient registration timelines for Oclacitinib-based veterinary products.
Packaging & Logistics
Oclacitinib maleate is packaged for stability and international shipping compliance:
- Primary: Double polyethylene bags with desiccant, nitrogen-purged
- Secondary: HDPE containers (100g, 500g, 1 kg, 5 kg) or fiber drums (10 kg, 25 kg)
- Tamper-evident seals on all packaging units
- Storage: Below 25°C, protected from light and moisture
- Shelf life: 24 months from date of manufacture
We ship worldwide via pharmaceutical logistics providers, offering FOB, CIF, and DDP terms. Typical lead time is 15-20 business days for standard quantities.
Competitive Pricing & Supply Reliability
As one of the few qualified Chinese manufacturers of Oclacitinib maleate API, we offer competitive pricing reflecting our synthesis optimization and production efficiency:
- Optimized synthesis route with high overall yield and minimal waste generation
- In-house production of key intermediates reducing supply chain costs
- Scalable production from gram-scale samples to ton-scale commercial supply
- Responsive production scheduling with 3-4 week lead times for stock items
We accommodate evaluation quantities (10g-100g) for formulation development, pilot-scale orders (1-10 kg), and commercial supply contracts. Volume-based pricing with annual agreement options provides budget predictability. Contact our veterinary API team for competitive quotations and technical documentation.